PET clinical study of novel antipsychotic LB-102 demonstrates unexpectedly prolonged dopamine receptor target engagement.
Wong DF, Chand GB, Caito N, Eramo A, Grattan VT, Hixon MS, Nicol G, Lessie E, Prensky Z, Kuwabara H, Tian L, Valenta I, Schindler TH, Gründer G, Vaino AR.
Wong DF, et al. Among authors: kuwabara h.
Neuropsychopharmacology. 2024 Dec;50(2):372-377. doi: 10.1038/s41386-024-01951-x. Epub 2024 Oct 16.
Neuropsychopharmacology. 2024.
PMID: 39414986
Free PMC article.
Clinical Trial.